{"groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"FG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"FG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"FG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"20"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"11"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"31"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"24"}],"type":"Global Deterioration of Health Status"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"No Longer Meets Eligibility Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"137"},{"groupId":"FG001","numSubjects":"125"},{"groupId":"FG002","numSubjects":"94"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Non-Compliance With Study Drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"188"},{"groupId":"FG001","numSubjects":"188"},{"groupId":"FG002","numSubjects":"190"}],"comment":"This table included all randomized participants.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"187"},{"groupId":"FG001","numSubjects":"182"},{"groupId":"FG002","numSubjects":"177"}],"comment":"Participants received at least 1 dose of study drug.","type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"comment":"Participants were considered completed when at least one drug of the combination is completed.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"188"},{"groupId":"FG001","numSubjects":"188"},{"groupId":"FG002","numSubjects":"190"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Data reported based on last participant last visit (LPLV) date (12 July 2022)."}